Altimmune Inc  

(Public, NASDAQ:ALT)   Watch this stock  
Find more results for ALT
2.66
0.00 (0.00%)
After Hours: 2.70 +0.04 (1.50%)
Oct 20, 5:08PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.55 - 2.74
52 week 0.63 - 35.00
Open 2.55
Vol / Avg. 90,858.00/124,529.00
Mkt cap 41.46M
P/E 0.10
Div/yield 29.10
EPS 27.25
Shares 15.59M
Beta 1.72
Inst. own 17%
Nov 2, 2017
Q3 2017 Altimmune Inc Earnings Release (Estimated) Add to calendar
Sep 26, 2017
Altimmune Inc at Ladenburg Thalmann Healthcare Conference
Sep 12, 2017
Altimmune Inc at Rodman & Renshaw Global Investment Conference
Aug 10, 2017
Q2 2017 Altimmune Inc Earnings Call
Aug 10, 2017
Q2 2017 Altimmune Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -102.38% 3706.44%
Operating margin -132.04% -215.37%
EBITD margin - -212.63%
Return on average assets -22.36% 158.51%
Return on average equity -26.92% 1073.74%
Employees 13 -
CDP Score - -

Address

19 Firstfield Rd
GAITHERSBURG, MD 20878-1791
United States - Map
+1-240-6541450 (Phone)
+1-302-6745266 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Altimmune, Inc., formerly Pharmathene, Inc., is a clinical-stage immunotherapeutic company. The Company focuses in development of medical counter measures against biological and chemical threats. The Company is involved in development of two next generation anthrax vaccines. It has two proprietary platform technologies, RespirVec and Densigen. Its candidates include NasoVAX, HepTcell, NasoShield and Oncosyn. NasoVAX is an intranasally administered recombinant influenza vaccine. The Company has completed Phase I clinical trials of NasoVAX. HepTcell is being tested as an immunotherapy for patients chronically infected with the hepatitis B virus. NasoShield is an intranasal, single-dose anthrax vaccine designed to provide rapid, stable protection after one intranasal administration. Oncosyn is being developed as a cancer immunotherapeutic product candidate. Oncosyn targets multiple tumor antigens simultaneous to prevent tumor escape.

Officers and directors

David J. Drutz M.D. Chairman of the Board
Age: 78
Bio & Compensation  - Reuters
William Enright President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Elizabeth A. Czerepak Chief Financial Officer, Executive Vice President - Corporate Development
Age: 61
Bio & Compensation  - Reuters
M. Scot Roberts Ph.D. Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
Sybil Tasker M.D. Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Philip L. Hodges Director
Age: 48
Bio & Compensation  - Reuters
Mitchel B. Sayare Ph.D. Director
Age: 69
Bio & Compensation  - Reuters
Klaus O. Schafer M.D. Director
Age: 67
Bio & Compensation  - Reuters
Derace L. Schaffer M.D. Independent Director
Age: 69
Bio & Compensation  - Reuters